Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2005

View Archived Issues

Favorable results reported for pegaptanib in wet AMD and DME

AstraZeneca recaps Q1 developments

DA-7218: a novel antimycobacterial agent

AN-53 exerts antiopiate activity in vitro and in vivo

Update on the Na-ASP-2 vaccine for hookworm infection

Interferon gamma-1b found to reduce mortality in patients with IPF

AnGes inlicenses nonviral gene delivery technology from Vical

Salmedix obtains license to anticancer drug technology from Myriad Genetics

NRP-104 reaches primary and secondary endpoints in phase III ADHD trial

Razadyne ER once-daily now available

Macugen approved in Canada and Brazil

Phase II study of MN-001 in interstitial cystitis begins

Patient enrollment complete in phase IIa trial with rNAPc2 for ACS

Preclinical data on TZP-101, a novel GHS-R1a agonist, for the treatment of gastric motility disorder

Cytheris acquires license to new immunomodulating agent activating NKT cells

HCV-796 moves into phase Ib trial in hepatitis C patients

First patient treated in phase I/II trial of NF-kappaB Decoy

Isis and Pfizer form ophthalmic antisense drug discovery collaboration

IKK2 inhibitors prevent inflammatory mediator expression: potential efficacy against asthma

Antiasthma efficacy of the novel syncretic CRx-170 shown in preclinical studies

NAALADase inhibitor delays prostate cancer growth and reduces taxol-induced neuropathy in mice

Unbalanced chromosome arm 11q loss of heterozygosity predicts pediatric neuroblastoma outcome

Alcon receives approvable letter from FDA for Retaane AMD treatment

Phase II ONO-2506 study discontinued

Encysive Pharmaceuticals submits NDA for Thelin

Data on dapoxetine for premature ejaculation presented at AUA

PT-141 increases sildenafil efficacy in erectile dysfunction

Telomerase reverse transcriptase vaccination active in metastatic prostate cancer

Recent patents cover novel treatments for cognitive disorders

New agents for treating obesity disclosed by Bristol-Myers Squibb

Recent patents report novel agents for lipoprotein disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...